Skip to main content
. 2018 Mar 8;25(1):750–756. doi: 10.1080/10717544.2018.1446473

Figure 1.

Figure 1.

125I-BMP-2 and 125I-MMP10 (%) remaining at the implantation site after injection of free125I-MMP formulation (S-125I-MMP) and after injection of the microsphere systems M-125I-MMP and M-125I-BMP into the calvaria defects in mice.